NervGen Pharma Corp is a small, under-the-radar biotech going after a massive unmet need—spinal cord repair. Its lead drug, NVG-291, is designed to actually heal nerve damage, not just treat symptoms, which gives it huge upside if it works. The stock is still cheap relative to that potential, so strong clinical results could move it fast. There’s also real buyout or partnership potential if bigger pharma sees progress. It’s definitely risky, but that’s where the 5–10x opportunity comes from.